CAPR

Capricor Therapeutics Inc

23.80

Jun 29 • 04:00PM ET -2.64 (-9.98%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR RYTM NUVL BMRN MDGL INCY KRYS VKTX AXSM NBIX

| Held by: XBI VTI IWM VXF IWO VTWO VHT DWAS VFMO PTH

Scroll to Statements

Index	RUT
Market Cap	1.38B
Enterprise Value	1.12B
Income	-114.59M
Sales	0.00M
Book/sh	4.83
Cash/sh	4.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	231
IPO	Jun 20, 2002

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	4.92
P/C	4.95
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	8.42
Current Ratio	8.42
Debt/Eq	0.08
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-2.31
EPS next Y	-0.69
EPS next Q	-0.59
EPS this Y	89.72%
EPS next Y	-197.61%
EPS next 5Y	-
EPS past 3/5Y	-24.12% -20.84%
Sales past 3/5Y	- -
EPS Y/Y TTM	-62.96%
Sales Y/Y TTM	-100.00%
EPS Q/Q	-10.57%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	-16.26% -

Insider Own	9.67%
Insider Trans	-4.64%
Inst Own	59.05%
Inst Trans	7.89%
ROA	-47.74%
ROE	-56.40%
ROIC	-39.16%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.61%
SMA50	-20.49%
SMA200	7.99%
Trades

Shs Outstand	57.66M
Shs Float	52.31M
Short Float	22.37%
Short Ratio	10.18
Short Interest	11.70M
52W High	40.37 -41.05%
52W Low	4.30 453.49%
Volatility	7.15% 5.45%
ATR (14)	1.90
RSI (14)	35.19
Beta	0.44
Rel Volume	2.91
Avg Volume	1.15M
Volume	3,242,160

Perf Week	-18.88%
Perf Month	-18.24%
Perf Quarter	-17.65%
Perf Half Y	-19.81%
Perf YTD	-17.53%
Perf Year	113.45%
Perf 3Y	395.83%
Perf 5Y	349.06%
Perf 10Y	-42.57%
Recom	1.00
Target Price	53.60
Prev Close	26.44
Price	23.80
Change	-9.98%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-30-25	Initiated	Alliance Global Partners	Buy	$20
Jun-26-25	Initiated	B. Riley Securities	Buy	$21
May-20-25	Initiated	Roth Capital	Buy	$31
Oct-21-24	Initiated	Piper Sandler	Overweight	$35
May-17-24	Initiated	Oppenheimer	Outperform	$14
Jan-05-24	Initiated	Cantor Fitzgerald	Overweight	$8
Oct-26-22	Initiated	Ladenburg Thalmann	Buy	$15
Dec-26-18	Downgrade	Maxim Group	Buy → Hold
Jan-26-18	Reiterated	H.C. Wainwright	Buy	$6.50 → $8.60
Sep-15-17	Reiterated	H.C. Wainwright	Buy	$2.15 → $6.50
Feb-13-17	Resumed	Rodman & Renshaw	Buy	$14
Jul-06-16	Resumed	H.C. Wainwright	Buy	$13
Jun-15-16	Initiated	ROTH Capital	Buy

Show Previous Ratings

Today 12:15AM	CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review (Stocktwits)
Jun-26-26 11:58AM	Capricors Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch CAPR Stock Slides 11% (Stocktwits) -13.03%
10:02AM	Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
09:05AM	Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference (GlobeNewswire)
Jun-17-26 10:24AM	All Eyes On Capricor Therapeutics Ahead Of Crucial Hearing On DMD Therapy Agreement CAPR Stock Jumps 6% (Stocktwits) +7.29%
09:25AM	Loading…
Jun-08-26 09:25AM	Capricor Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-13-26 01:02AM	Capricor Therapeutics Inc (CAPR) Q1 2026 Earnings Call Highlights: Strong Cash Position Amid ... (GuruFocus.com)
May-12-26 04:21PM	Capricor: Q1 Earnings Snapshot (Associated Press)
04:05PM	Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-11-26 06:00AM	Inhibrx delivers differentiated cancer drug data; Fractyl starts diabetes gene therapy trial (BioPharma Dive) +5.00%
May-04-26 04:05PM	Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 (GlobeNewswire) +8.38%
Apr-22-26 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting (GlobeNewswire)
Mar-25-26 07:30AM	Caprock Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at Destiny (TMX Newsfile)
Mar-23-26 10:50AM	Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp. (TMX Newsfile)
Mar-12-26 11:07PM	Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ... (GuruFocus.com) -8.74%
04:27PM	Loading…
04:27PM	Capricor: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
09:00AM	Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-10-26 10:47AM	Capricor Therapeutics Stock Jumps As FDA Resumes Deramiocel Review (Benzinga) +9.04%
09:25AM	Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA (GlobeNewswire)
07:00AM	Xenon hits a home run in epilepsy; FDA restarts review of Duchenne cell therapy (BioPharma Dive)
Mar-09-26 01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +9.78%
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:30AM	Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12 (GlobeNewswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal)
Feb-24-26 09:00AM	Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference (GlobeNewswire)
Jan-21-26 10:49AM	CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February (Zacks)
Jan-20-26 09:15AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data (GlobeNewswire)
Jan-09-26 06:01AM	Here's Why This Biotechnology Skyrocketed by 439% in December (Motley Fool) -6.69%
Dec-18-25 01:14PM	Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory (Insider Monkey)
04:05PM	Loading…
Dec-16-25 04:05PM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy (GlobeNewswire)
Dec-05-25 10:34AM	CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know (Zacks) +5.87%
06:15AM	Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock (GlobeNewswire)
Dec-04-25 04:01PM	Capricor Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -15.22%
Dec-03-25 01:03PM	Capricor Skyrockets 535% After Getting Vindication In Muscular Dystrophy (Investor's Business Daily) +371.07%
10:36AM	Biotech Stock Up Over 400% After Late-Stage Breakthrough (Schaeffer's Research)
07:20AM	Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy (GlobeNewswire)
06:10AM	Capricor soars on positive results for Duchenne cell therapy (BioPharma Dive)
Nov-24-25 09:00AM	Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025 (GlobeNewswire) -19.30%
Nov-11-25 12:00AM	Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) +11.51%
Nov-10-25 04:50PM	Capricor: Q3 Earnings Snapshot (Associated Press Finance) -6.24%
04:01PM	Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 06:05PM	CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-03-25 09:15AM	Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel (GlobeNewswire) -6.76%
Oct-31-25 09:15AM	Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 (GlobeNewswire)
Oct-30-25 09:23AM	Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last? (Zacks) -10.26%
Sep-26-25 06:45AM	Capricor (CAPR) Surges 5.3%: Is This an Indication of Further Gains? (Zacks) +8.74%
Sep-25-25 07:15AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting (GlobeNewswire) +5.33%
06:50AM	Capricor readies revised FDA pitch for Duchenne cell therapy (BioPharma Dive)
Sep-10-25 07:43AM	Capricor refutes FDAs DMD deramiocel rejection in public statement (Pharmaceutical Technology)
Sep-09-25 09:20AM	Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel (GlobeNewswire)
Sep-02-25 03:40AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-28-25 04:21PM	Investors in Capricor Therapeutics, Inc. (CAPR): Protect Your Rights - Contact Levi & Korsinsky Before September 15, 2025 (Newsfile)
Aug-25-25 09:22AM	Did You Lose Money on Capricor Therapeutics, Inc. (CAPR)? Levi & Korsinsky Urges Investors to Act Before September 15, 2025 (Newsfile) -7.04%
Aug-21-25 04:20PM	Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025 - Contact Levi & Korsinsky (Newsfile)
Aug-18-25 09:00AM	Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine (GlobeNewswire)
08:28AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Aug-15-25 09:15AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR (PR Newswire)
Aug-14-25 04:26PM	Capricor Therapeutics, Inc. (CAPR) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 15, 2025 (Newsfile) -6.27%
Aug-12-25 09:30AM	Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
03:05AM	Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
Aug-11-25 06:06PM	Capricor: Q2 Earnings Snapshot (Associated Press Finance) -13.84%
04:05PM	Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
11:01AM	Controversial FDA regulator back 12 days after resigning (Quartz)
06:22AM	Wall St futures steady, chip stocks slip on China sales deal (Reuters)
Aug-08-25 08:30AM	Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA (GlobeNewswire) +12.39%
Aug-07-25 06:35PM	Quanterix Corporation (QTRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-06-25 09:00AM	Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13 (GlobeNewswire)
Aug-05-25 10:45AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire)
Jul-29-25 08:23AM	Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025 - Contact Levi & Korsinsky (Newsfile)
Jul-28-25 09:00AM	Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Jul-25-25 08:07AM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (PR Newswire) +8.95%
Jul-22-25 04:26PM	Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR (Business Wire)
10:05AM	FDA Rejects Replimunes Skin Cancer Treatment, Shares Sink (Bloomberg)
Jul-21-25 04:46PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 15, 2025 - Capricor Therapeutics, Inc. (CAPR) (Newsfile) -8.87%
Jul-14-25 11:33AM	FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks (Zacks)
Jul-11-25 10:50AM	Capricor Therapeutics Hammered On A Surprise FDA Rejection (Investor's Business Daily) -32.98%
06:30AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-25-25 12:15PM	No Ad Comm not necessarily positive for Capricor, says Roth Capital (TipRanks) +8.65%
11:05AM	Capricors deramiocel moves ahead without AdCom, says H.C. Wainwright (TipRanks)
08:56AM	Capricor (CAPR) Moves 20.4% Higher: Will This Strength Last? (Zacks)
Jun-24-25 09:00AM	Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy (GlobeNewswire) +20.44%
Jun-21-25 09:30AM	Capricor Therapeutics announces four-year data from HOPE-2 OLE study (TipRanks)
Jun-20-25 09:25AM	Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy (GlobeNewswire) -30.82%
Jun-17-25 09:00AM	Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program (GlobeNewswire)
Jun-12-25 09:35AM	Capricor says FDA inspection brought Form 483 with several observations (TipRanks) +6.09%
Jun-11-25 09:25AM	Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program (GlobeNewswire) -5.40%
May-21-25 11:22AM	Capricor Therapeutics, Inc.'s (CAPR): Analysts See 489% Upside Potential (Insider Monkey)
May-14-25 03:15AM	Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com) +5.07%
May-13-25 04:19PM	Capricor: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
09:00AM	Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer (GlobeNewswire)
May-12-25 09:37AM	What To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings (GuruFocus.com) +12.15%
May-06-25 09:15AM	Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 (GlobeNewswire) -29.13%
May-05-25 08:00AM	Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy (GlobeNewswire) -13.15%
Apr-21-25 05:02PM	Capricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ... (GuruFocus.com) +5.96% +16.53%
08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-01-25 09:00AM	Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day (GlobeNewswire)
Mar-21-25 06:23PM	Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -10.45%

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy ("DMD"), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

M.D.Dr. Frank Isaac Litvack FACC

Co-FounderDr. Linda Marban Ph.D.

CFO & Corporate TreasurerMr. Anthony J. Bergmann M.B.A.

J.D.Ms. Karen G. Krasney Esq.

Chief Operating & Science OfficerDr. Kristi A. H. Elliott Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Krasney Karen	EVP, GENERAL COUNSEL	Jun 25 '26	Option Exercise	3.18	24,100	76,638	54,647	Jun 29 09:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 25 '26	Sale	30.38	24,100	732,158	30,547	Jun 29 09:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 25 '26	Option Exercise	3.18	24,100	76,638	35,323	Jun 29 09:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 25 '26	Sale	30.38	24,100	732,158	11,223	Jun 29 09:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 22 '26	Option Exercise	3.18	500	1,590	31,047	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 24 '26	Option Exercise	3.18	400	1,272	30,947	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 22 '26	Sale	30.00	500	15,000	30,547	Jun 24 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Jun 24 '26	Sale	30.00	400	12,000	30,547	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 22 '26	Option Exercise	3.18	500	1,590	11,723	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 24 '26	Option Exercise	3.18	400	1,272	11,623	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 22 '26	Sale	30.00	500	15,000	11,223	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Jun 24 '26	Sale	30.00	400	12,000	11,223	Jun 24 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 18 '26	Option Exercise	1.39	3,000	4,170	11,223	May 19 04:15 PM
Musket David B	Director	May 19 '26	Proposed Sale	27.00	88,788	2,397,256		May 19 11:40 AM
Litvack Frank	Director	May 13 '26	Option Exercise	1.39	3,937	5,472	133,776	May 14 05:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	May 01 '26	Option Exercise	3.18	25,000	79,500	55,547	May 04 04:30 PM
Krasney Karen	EVP, GENERAL COUNSEL	May 01 '26	Sale	31.70	25,000	792,548	30,547	May 04 04:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 01 '26	Option Exercise	3.18	25,000	79,500	33,223	May 04 04:30 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	May 01 '26	Sale	31.70	25,000	792,540	8,223	May 04 04:30 PM
Sabar Karimah Es	Director	Apr 02 '26	Option Exercise	3.18	7,529	23,942	7,529	Apr 03 05:00 PM
Sabar Karimah Es	Director	Apr 02 '26	Sale	32.00	7,529	240,928	0	Apr 03 05:00 PM
Karimah Es Sabar	Director	Apr 02 '26	Proposed Sale	30.12	7,529	226,773		Apr 02 04:24 PM
Krasney Karen	EVP, GENERAL COUNSEL	Mar 31 '26	Option Exercise	3.61	25,000	90,293	55,547	Apr 01 08:00 PM
Krasney Karen	EVP, GENERAL COUNSEL	Mar 31 '26	Sale	30.12	25,000	752,935	30,547	Apr 01 08:00 PM
Sabar Karimah Es	Director	Mar 31 '26	Option Exercise	4.86	61,265	297,748	61,265	Apr 01 08:00 PM
Sabar Karimah Es	Director	Apr 01 '26	Option Exercise	4.86	53,735	261,152	53,735	Apr 01 08:00 PM
Sabar Karimah Es	Director	Mar 31 '26	Sale	30.17	61,265	1,848,243	0	Apr 01 08:00 PM
Sabar Karimah Es	Director	Apr 01 '26	Sale	31.03	53,735	1,667,225	0	Apr 01 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Mar 31 '26	Option Exercise	3.18	25,000	79,500	33,223	Apr 01 08:00 PM
Bergmann Anthony	CHIEF FINANCIAL OFFICER	Mar 31 '26	Sale	30.13	25,000	753,152	8,223	Apr 01 08:00 PM
Karen Krasney	Officer	Mar 31 '26	Proposed Sale	27.77	75,000	2,082,750		Mar 31 04:23 PM
ANTHONY BERGMANN	Officer	Mar 31 '26	Proposed Sale	27.77	75,000	2,082,750		Mar 31 04:23 PM
Karimah Es Sabar	Director	Mar 31 '26	Proposed Sale	27.77	115,000	3,193,550		Mar 31 04:22 PM
Krasney Karen	EVP, GENERAL COUNSEL	Dec 30 '25	Option Exercise	1.39	2,500	3,475	30,547	Mar 27 07:15 PM
DUNBAR GEORGE W JR	Director	Dec 19 '25	Option Exercise	1.39	3,000	4,170	14,306	Dec 23 02:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

CAPR

Capricor Therapeutics Inc

Upgrade your Finviz experience